~~<i id='436FD1FD8C'><strike id='436FD1FD8C'><tt id='436FD1FD8C'><pre id='436FD1FD8C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：comprehensive 2025-09-30 13:14:03 - browse：445

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

focus

leisure time

knowledge

focus

ResearchersatNYUduringahackathontobuildanMRIfromscratch.CourtesyNYUHowmanyscientistsdoesittaketobuil

WSS

Does good food count as health care? Study aims to find out

A daunting task: navigating dual Medicare, Medicaid eligibility

U.K. researchers warn about biases in medical devices, algorithms

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Poor hospice wound care hurts patients and families

Readout LOUD podcast: A CRISPR milestone, biotech mixology

leisure time

fashion

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth increases loan offers after Change Healthcare outage

Medical leaders decry Supreme Court decision on affirmative action

Hospitals look to new technology to keep health care workers safe

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bluebird, CVS, Contineum

Malaria cases in Florida and Texas: Here’s what you need to know

U.K. researchers warn about biases in medical devices, algorithms

Drug repurposing or repositioning? The language matters

FDA's Woodcock to retire early next year

focus

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Plastic surgeons increase patient psychiatric screenings

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Wegovy, Zepbound and weight loss drugs that preserve muscle

Readout Newsletter: Bluebird, CVS, Contineum

SCOTUS questions limit to govt efforts to fight misinformation

focus

leisure time

knowledge

focus